SALT LAKE CITY– Purgo Scientific, an innovative medical device company focused on advancing next-generation drug delivery technologies, today announced the appointment of James A. Bowman as its new Chief Executive Officer.
Bowman is a seasoned healthcare executive with over 20 years of experience leading early-stage life sciences companies and bringing disruptive medical and surgical technologies to market. With a background in biomedical engineering and executive training from Harvard Business School’s Owner/President Management program, Bowman brings a powerful combination of technical expertise, strategic vision, and operational leadership to Purgo Scientific.
Throughout his career, Bowman has successfully guided multiple MedTech companies from early innovation through commercialization and strategic exits. He has raised venture and institutional capital, built high-performing teams, and launched products across a wide range of specialties including general surgery, orthopedics, neurosurgery, cardiothoracic, gynecology, imaging, and oncology.
Bowman succeeds Mike Benjamin, who is stepping down from his role as CEO for personal health reasons. Benjamin will continue to play an active role in the company as Chairman of the Board. Under his leadership, Purgo Scientific achieved significant milestones, including advancing its lead technology through key development phases, securing funding, and assembling a strong team. The company extends its deep appreciation for his leadership, vision, and ongoing commitment to its mission.
“Jim is exactly the kind of leader we need at this pivotal stage of our growth,” said Mike Benjamin, Chairman of the Board. “His proven track record in bringing innovative surgical and drug delivery solutions to market, along with his operational excellence, makes him the ideal person to lead Purgo into its next phase.”
“I’m honored to join Purgo Scientific and build on the strong foundation Mike and the team have laid,” said Bowman. “With Purgo’s unique platform technology and solid scientific foundation, we’re well-positioned to improve patient outcomes and establish a new standard of care in localized therapy.”
Purgo Scientific’s lead innovation, currently under regulatory development, represents a significant advancement in site-specific drug delivery with applications in both human and veterinary medicine. Under Bowman’s leadership, the company plans to accelerate product development, form strategic partnerships, and position itself for long-term success in the healthcare sector.
